Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer

HAMID, Fatma F. Abdel; SOLIMAN, Ahmed F.; ABDELGAWAD, Iman A.; MALASH, Ibrahim; Wadaa-Allah, Ahmed; IBRAHIM, Noha

doi:10.1515/tjb-2019-0323

Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer

Ahmed M. Wadaa ALLAH, (Ain Shams University, Faculty of Science, Biochemistry Department, Egypt)

Fatma F. Abdel HAMID, (Ain Shams University, Faculty of Science, Biochemistry Department, Egypt)

Ahmed F. SOLIMAN, (Ain Shams University, Faculty of Science, Biochemistry Department, Egypt)

Noha IBRAHIM, (Cairo University, National Cancer Institute, Department of Clinical and Chemical Pathology, Egypt)

Ibrahim MALASH, (Cairo University, National Cancer Institute, Medical Oncology Department, Egypt)

Iman A. ABDELGAWAD (Cairo University, National Cancer Institute, Department of Clinical and Chemical Pathology, Egypt)

Türk Biyokimya Dergisi

0 0

Yıl: 2020 Cilt: 45 Sayı: 5 Sayfa Aralığı: 525 - 532 Metin Dili: İngilizce DOI: 10.1515/tjb-2019-0323 İndeks Tarihi: 18-11-2021

Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer

Öz:

Background: Prostate cancer (PC) incidence has risenglobally. As there are no current independent biomarkerswith high diagnostic efficiency to detect PC, this studywas performed to investigate the relative gene expressionlevels of E2F3 and survivin in the whole blood of PC,benign prostate hyperplasia (BPH), and normal controlindividuals and to explore their diagnostic value.Material and methods: Participants of the study weredivided into three groups; normal control group (n=25),BPH patients (n=25), and PC patients (n=75). The E2F3 andsurvivin gene expression levels were assessed using realtime qPCR in addition to the measurement of free and totallevels of prostate-specific antigen (PSA) using electrochemiluminescence assays.Results: Survivin relative gene expression was overexpressed in PC and BPH patients compared to thenormal control group, whereas, E2F3 did not differ significantly among the studied groups. Compared to PSA, E2F3and survivin mRNA expression levels had lower diagnosticefficacy to differentiate PC from normal and BPH individuals with an area under curve (AUC) of 0.471 and0.727, respectively. Further, survivin expression level wasassociated with increased the risk of PC.Conclusion: Survivin and E2F3 relative expression levels inperipheral blood had low diagnostic performance to detectPC and individuals with high survivin expression levelsmay have higher risk to develop PC.

Anahtar Kelime:

Öz:

Amaç: Prostat kanseri insidansı global olarak artmaktadır. Prostat kanserini saptayacak yüksek tanısal etkinlikte güncel bağımsız biyobelirteçler olmaması nedeniyle, bu çalışma E2F3 ve survivin genlerinin göreceli ekspresyon düzeylerinin tam kanda benign prostat hiperplazisi (BPH), prostat kanseri (PC) ve normal kontrollerde incelenmesi amacıyla yapılmıştır. Gereç ve Yöntem: Katılımcılar normal kontrol (n=25), BPH hastaları (n=25) ve PC hastalrı olarak üç gruba ayrılmıştır. E2F3 ve surviving gen ekspresyonları gerçek zamanlı qPCR yöntemiyle, serbest ve total prostat spesifik antijen (PSA) düzeyleri ise elektrokemilüminesans yöntemi ile ölçülmüştür. Bulgular: Survivin geminin ekspresyonu PC ve BPH has talarında normal kontrollere göre artmış bulunup, E2F3 gen ekspresyonunda çalışma grupları arasında anlamlı fark bulunamamıştır PSA ile kıyaslandığında, E2F3 ve surviving mRNA ekspresyon düzeylerinin PC hastalarını normal kontrol ve BPH hastalarından ayırıcılığının düşük tanısal etkinliği olduğu sırasıyla AUC değerlerinin 0,727 ve 0,471 bulunması ile gösterilmiştir. Ayrıca, survivin ekspresyon düzeyinin prostat kanseri riskini arttırdığı gösterilmiştir. Sonuç: Survivin ve E2F3 genlerinin periferik kandaki göreceli ekspresyon düzeyleri prostat kanserinin saptan masında düşük tanısal performanslıdır ve yüksek survivin ekspresyon düzeyleri olan bireylerde prostat kanseri gel işme riski daha yüksektir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, et al. Global Burden of Disease Cancer Collaboration, Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study, JAMA Oncol 4 (2018) 1553–1568.
2. Pernar CH, Ebot EM, Wilson KM, Mucci LA, The epidemiology of prostate cancer, Cold Spring Harb Perspect Med 8 (2018) a030361.
3. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144:1941–53.
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
5. Brawer MK. Prostate-specific antigen. Semin Surg Oncol 2000; 18:3–9.
6. Bai VU, Kaseb A, Tejwani S, Divine GW, Barrack ER, Menon M, et al. Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine. Proc Natl Acad Sci 2007;104:2343–8.
7. Alzghoul S, Hailat M, Zivanovic S, Que L, Shah GV. Measurement of serum prostate cancer markers using a nanopore thin film based optofluidic chip. Biosens Bioelectron 2016;77:491–8.
8. Gómez-Gómez E, Jiménez-Vacas JM, Pedraza-Arévalo S, LópezLópez F, Herrero-Aguayo V, Hormaechea-Agulla D, et al., Oncogenic role of secreted engrailed homeobox 2 (EN2) in prostate cancer, J Clin Med 8 (2019) 1400.
9. Jiménez-Vacas JM, Gómez-Gómez E, Montero-Hidalgo AJ, HerreroAguayo V, L-López F, Sánchez-Sánchez R. Clinical utility of ghrelin-O-acyltransferase (GOAT) enzyme as a diagnostic tool and potential therapeutic target in prostate cancer. J Clin med 2019;8:pii E2056. http://doi.org/10.3390/jcm8122056.
10. Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol 2016;70: 740–8.
11. Eder IE, Bektic J, Haag P, Bartsch G, Klocker H. Genes differentially expressed in prostate cancer. BJU Int 2004;93:1151–5.
12. Pipinikas CP, Nair SB, Kirby RS, Carter ND, Fenske CD. Measurement of blood E2F3 mRNA in prostate cancer by quantitative RT-PCR: a preliminary study. Biomarkers 2007;12: 541–57.
13. Gao Y, Feng B, Lu L, Han S, Chu X, Chen L, et al. MiRNAs and E2F3: a complex network of reciprocal regulations in human cancers. Oncotarget 2017;8:60624–39.
14. Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, et al. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 2004; 23:5871–9.
15. Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A, et al. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 2004;23:1627–30.
16. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA. Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem 2004;279:40511–20.
17. Zangemeister-Wittke U, Simon HU. An IAP in action: The multiple roles of survivin in differentiation, immunity and malignancy. Cell Cycle 2004;3:1121–3.
18. Xing Z, Conway EM, Kang C, Winoto A. Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med 2004;199:69–80.
19. Khan Z, Khan AA, Yadav H, Prasad GBKS, Bisen PS. Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma. Cell Mol Biol Lett 2017;22:8.
20. Mera S, Magnusson M, Tarkowski A, Bokarewa M. Extracellular survivin up-regulates adhesion molecules on the surface of leukocytes changing their reactivity pattern. J Leukoc Biol 2008; 83:149–55.
21. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581–9.
22. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46–54.
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402–8.
24. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. 2001, CA Cancer J Clin 51 (2001) 15–36.
25. Pentyala S, Whyard T, Pentyala S, Muller J, Pfail J, Parmar S, et al. Prostate cancer markers: An update. Biomed Rep 4 (2016) 263–268.
26. Yie S, Lou B, Ye S, Cao M, He X, Li P, et al. Detection of survivinexpressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. Ann Surg Oncol 2008;15:3073–82.
27. Tang XP, Li J, Yu LC, Chen YC, Shi SB, Zhu LR, et al. Clinical significance of survivin and VEGF mRNA detection in the cell fraction of the peripheral blood in non-small cell lung cancer patients before and after surgery. Lung Cancer 2013;81:273–9.
28. Cao M, Yie SM, Wu SM, Chen S, Lou B, He X, et al. Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance. Clin Exp Metastasis 2009;26:751–8.
29. Gunaldi M, Isiksacan N, Kocoglu H, Okuturlar Y, Gunaldi O, Topcu TO, et al., The value of serum survivin level in early diagnosis of cancer, J Cancer Res Ther 14 (2018) 570–573.
30. Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med 2005;9:360–72.
31. Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 2004;100: 751–7.
32. Eslami M, Khamechian T, Mazoochi T, Ehteram H, Sehat M, Alizargar J. Evaluation of survivin expression in prostate specimens of patients with prostate adenocarcinoma and benign prostate hyperplasia underwent transurethral resection of the prostate or prostatectomy. Springerplus 2016;5:621.
33. Tian P, Shen Y, Wan C, Yang T, An J, Yi Q, et al. Diagnostic value of survivin for malignant pleural effusion: a clinical study and metaanalysis. Int J Clin Exp Pathol 2014;7:5880–7.
34. Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC, et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004;171: 626–30.
35. Olsson AY, Feber A, Edwards S, Te Poele R, Giddings I, Merson S, et al. Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. Oncogene 2007; 26:1028–37.
36. Rodriguez JF, Eggener SE, Prostate cancer and the evolving role of biomarkers in screening and diagnosis, Radiol Clin North Am 56 (2017) 187–196.
37. Hoffman RM, Gilliland FD, Adams-Cameron M, Hunt WC, Key CR. Prostate-specific antigen testing accuracy in community practice. BMC Fam Pract 2002;3:19.
38. Lojanapiwat B, Anutrakulchai W, Chongruksut W, Udomphot C. Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice. Prostate Int 2014;2:133–9.
39. Holmström B, Johansson M, Bergh A, Stenman U-H, Hallmans G, Stattin P. Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ 2009;339:b3537.
40. Sriprasad S, Dew TK, Muir GH, Thompson PM, Mulvin D, Choi WH, et al. Validity of PSA, free/total PSA ratio and complexed/total PSA ratio measurements in men with acute urinary retention. Prostate Cancer Prostatic Dis 2001;4:167–72.
41. Abrahamsson PA, Lilja H, Oesterling JE. Molecular forms of serum prostate-specific antigen: The clinical value of percent free prostate-specific antigen. Urol Clin North Am 1997;24: 353–65.
42. Huang Y, Li ZZ, Huang YL, Song HJ, Wang YJ. Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: A meta-analysis. Medicine (Baltimore) 2018;97: e0249.
43. Thakur V, Singh PP, Talwar M, Mukherjee U, Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma, Dis Markers 19 (2003) 287–292.

APA	Wadaa-Allah A, HAMID F, SOLIMAN A, IBRAHIM N, MALASH I, ABDELGAWAD I (2020). Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer. , 525 - 532. 10.1515/tjb-2019-0323
Chicago	Wadaa-Allah Ahmed,HAMID Fatma F. Abdel,SOLIMAN Ahmed F.,IBRAHIM Noha,MALASH Ibrahim,ABDELGAWAD Iman A. Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer. (2020): 525 - 532. 10.1515/tjb-2019-0323
MLA	Wadaa-Allah Ahmed,HAMID Fatma F. Abdel,SOLIMAN Ahmed F.,IBRAHIM Noha,MALASH Ibrahim,ABDELGAWAD Iman A. Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer. , 2020, ss.525 - 532. 10.1515/tjb-2019-0323
AMA	Wadaa-Allah A,HAMID F,SOLIMAN A,IBRAHIM N,MALASH I,ABDELGAWAD I Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer. . 2020; 525 - 532. 10.1515/tjb-2019-0323
Vancouver	Wadaa-Allah A,HAMID F,SOLIMAN A,IBRAHIM N,MALASH I,ABDELGAWAD I Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer. . 2020; 525 - 532. 10.1515/tjb-2019-0323
IEEE	Wadaa-Allah A,HAMID F,SOLIMAN A,IBRAHIM N,MALASH I,ABDELGAWAD I "Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer." , ss.525 - 532, 2020. 10.1515/tjb-2019-0323
ISNAD	Wadaa-Allah, Ahmed vd. "Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer". (2020), 525-532. https://doi.org/10.1515/tjb-2019-0323

APA	Wadaa-Allah A, HAMID F, SOLIMAN A, IBRAHIM N, MALASH I, ABDELGAWAD I (2020). Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer. Türk Biyokimya Dergisi, 45(5), 525 - 532. 10.1515/tjb-2019-0323
Chicago	Wadaa-Allah Ahmed,HAMID Fatma F. Abdel,SOLIMAN Ahmed F.,IBRAHIM Noha,MALASH Ibrahim,ABDELGAWAD Iman A. Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer. Türk Biyokimya Dergisi 45, no.5 (2020): 525 - 532. 10.1515/tjb-2019-0323
MLA	Wadaa-Allah Ahmed,HAMID Fatma F. Abdel,SOLIMAN Ahmed F.,IBRAHIM Noha,MALASH Ibrahim,ABDELGAWAD Iman A. Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer. Türk Biyokimya Dergisi, vol.45, no.5, 2020, ss.525 - 532. 10.1515/tjb-2019-0323
AMA	Wadaa-Allah A,HAMID F,SOLIMAN A,IBRAHIM N,MALASH I,ABDELGAWAD I Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer. Türk Biyokimya Dergisi. 2020; 45(5): 525 - 532. 10.1515/tjb-2019-0323
Vancouver	Wadaa-Allah A,HAMID F,SOLIMAN A,IBRAHIM N,MALASH I,ABDELGAWAD I Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer. Türk Biyokimya Dergisi. 2020; 45(5): 525 - 532. 10.1515/tjb-2019-0323
IEEE	Wadaa-Allah A,HAMID F,SOLIMAN A,IBRAHIM N,MALASH I,ABDELGAWAD I "Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer." Türk Biyokimya Dergisi, 45, ss.525 - 532, 2020. 10.1515/tjb-2019-0323
ISNAD	Wadaa-Allah, Ahmed vd. "Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer". Türk Biyokimya Dergisi 45/5 (2020), 525-532. https://doi.org/10.1515/tjb-2019-0323